Core Viewpoint - Partners Value Split Corp. reported financial results for the year ended December 31, 2025, showing an increase in income available for distribution but a decrease in net comprehensive income compared to the previous year [1][2]. Financial Performance - Income available for distribution for 2025 was $94 million, up from $85 million in 2024, primarily due to an increase in the dividend rate by Brookfield Corporation and Brookfield Asset Management Ltd [2]. - Net comprehensive income for 2025 was $1.3 billion, a decrease from $2.6 billion in 2024, mainly due to lower unrealized mark-to-market gains on shares of Brookfield Corporation and Brookfield Asset Management [2][4]. Share Prices - As of December 31, 2025, the market prices for Brookfield Corporation (BN) and Brookfield Asset Management Ltd. (BAM) shares were $45.89 and $52.39, respectively. By March 25, 2026, these prices had decreased to $39.91 and $43.69 [3]. Income Breakdown - For the year ended December 31, 2025, the Company reported dividend income of $93.2 million and other investment income of $1.5 million, totaling $94.7 million in income [4]. - Management fees were $17, and administrative expenses were $372, leading to total expenses of $389 [4]. Distributions - Distributions paid on senior preferred shares and debentures amounted to $34.3 million, with $60.0 million available for distribution to junior preferred and capital shares [4]. Investment Holdings - As of December 31, 2025, the Company owned 179 million Class A Limited Voting shares of Brookfield Corporation and 25 million Class A Limited Voting shares of Brookfield Asset Management, generating cash flow through dividend payments [4][5]. Company Overview - Brookfield Corporation is a global investment firm with a focus on long-term wealth building, operating in alternative asset management, wealth solutions, and various sectors including renewable power and real estate [6]. - Brookfield Asset Management Ltd. manages over $1 trillion in assets across multiple sectors, emphasizing long-term investments in real assets and essential service businesses [7].

Core Viewpoint - Partners Value Investments Inc. reported a net loss of $1.4 billion for the year ended December 31, 2025, a significant reduction from a net loss of $3.8 billion in the previous year, primarily due to lower remeasurement losses on financial instruments [2]. Financial Performance - The Company recorded a net loss of $1.4 billion for 2025, down from $3.8 billion in 2024, attributed to reduced remeasurement losses on retractable common shares and warrants [2]. - Adjusted Earnings for 2025 were $66 million, a decrease from $122 million in 2024, influenced by unfavorable foreign currency movements and higher preferred share dividends [3]. - Investment income for 2025 totaled $145.2 million, compared to $127.0 million in 2024, with dividends increasing from $108.4 million to $117.5 million [5]. Investment Portfolio - As of December 31, 2025, the Company held 181 million Class A Limited Voting Shares of Brookfield Corporation and approximately 26 million Class A Limited Voting Shares of Brookfield Asset Management Ltd., representing approximately 8% and 2% interests, respectively [7][8]. - The market value of Brookfield Corporation shares was $45.89 and Brookfield Asset Management shares were $52.39 as of December 31, 2025, with subsequent declines noted by March 25, 2026 [4]. Assets and Liabilities - Total assets as of December 31, 2025, were $11.5 billion, an increase from $10.0 billion in 2024, with significant investments in Brookfield Corporation and Brookfield Asset Management [8]. - Liabilities increased to $10.5 billion in 2025 from $8.8 billion in 2024, with a notable rise in preferred shares and retractable common shares [8].

Core Viewpoint - Archrock, Inc. announces the retirement of Douglas S. Aron, Senior Vice President and Chief Financial Officer, by the end of 2026 or upon naming a successor, with an executive search firm engaged for the transition [1] Group 1: Leadership Transition - Douglas S. Aron has been a critical member of Archrock's leadership team, contributing to the company's transformation and improvement in balance sheet and profitability [2] - Aron expresses gratitude towards the Board and the team, indicating his commitment to a successful transition while looking forward to spending more time with family [3] Group 2: Company Overview - Archrock is an energy infrastructure company focused on midstream natural gas compression, committed to safe and environmentally responsible production, compression, and transportation of natural gas [4] - The company is headquartered in Houston, Texas, and is a leading provider of natural gas compression services and aftermarket services in the U.S. energy industry [4]

Core Viewpoint - MediPharm Labs Corp. is set to release its full year and fourth quarter financial results for the period ending December 31, 2025, on March 30, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for March 30, 2026, at 10:00 a.m. Eastern time [2] - Participants are encouraged to join the call approximately 15 minutes early [3] Group 2: Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms [5] - MediPharm Labs has invested in advanced technology and methodologies for the delivery of precision-dosed cannabis products [5] Group 3: Regulatory and Market Position - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale domestic GMP License for extracting multiple natural cannabinoids [6] - The company is currently pursuing foreign drug manufacturing site registration with the US FDA [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Insights - Ascentage Pharma reported significant advancements in its commercialization strategy and clinical pipeline for 2025, particularly with the launch of Lisaftoclax and the expansion of Olverembatinib's coverage in China's National Reimbursement Drug List (NRDL) [2][6][19] Financial Performance - Total revenue for 2025 was US$82.1 million, a decrease of 41.5% from US$134.3 million in 2024, primarily due to the absence of intellectual property revenue recorded in 2024 [19] - Product sales of Olverembatinib increased by 80.6% year-over-year to US$62.2 million, while sales of Lisaftoclax reached US$10.1 million during its first five months post-launch [6][19] - Selling and distribution expenses rose by 80.4% to US$50.6 million, attributed to increased commercialization activities [20] - Research and development expenses increased by 20.1% to US$162.7 million, reflecting higher clinical trial costs [21] - The company reported a loss of US$177.7 million for the year, compared to a loss of US$55.6 million in 2024 [25] Product and Pipeline Updates - Olverembatinib is the first third-generation BCR-ABL1 TKI approved in China for chronic myeloid leukemia (CML) patients with specific mutations and resistance to earlier treatments [3][32] - Lisaftoclax, a novel Bcl-2 inhibitor, was launched in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is undergoing multiple Phase III trials [34] - Nine registrational Phase III clinical trials are currently in progress for both Olverembatinib and Lisaftoclax, with several cleared by the FDA and EMA [6][12] Market and Commercialization Strategy - The number of hospitals where Olverembatinib is available increased by 12.4% to 825, with a notable 36.5% increase in hospitals on formulary for the drug [7] - The company aims to actively pursue the inclusion of Lisaftoclax in China's NRDL in 2026 [24] Upcoming Milestones - Continued enrollment in ongoing clinical trials for both Olverembatinib and Lisaftoclax, including POLARIS-1, POLARIS-2, POLARIS-3, and various GLORA studies [9][12][24] - Plans to initiate clinical studies for APG-3288, a novel BTK degrader, with an open-label Phase I study expected to commence [18]

Core Insights - G Mining Ventures Corp. reported strong financial and operational results for 2025, with Tocantinzinho achieving its first full year of commercial production, generating $255 million in free cash flow and demonstrating operational reliability [2][3][5]. Financial Performance - The company generated $580.7 million in revenue for the full year 2025, a significant increase from $145.3 million in 2024 [14][61]. - Net income for 2025 was reported at $288 million, or $1.27 per share, compared to $29.6 million in 2024 [15][62]. - Free cash flow for the year was $255 million, equating to $1.12 per share, highlighting the asset's strong margin profile [17][20]. Production and Cost Metrics - Gold production for 2025 totaled 171,871 ounces, with total cash costs averaging $748 per ounce, slightly above guidance due to increased royalty costs [5][12]. - The all-in sustaining cost (AISC) for the year was $1,155 per ounce, remaining within guidance despite higher costs [13][12]. - Fourth quarter production reached 47,346 ounces at total cash costs of $808 per ounce and AISC of $1,245 per ounce, benefiting from a higher realized gold price of $4,032 per ounce [7][14]. Operational Outlook - The company expects average annual production of 200,000 ounces over the next two years, with 2026 production estimated between 160,000 to 190,000 ounces and 200,000 to 235,000 ounces in 2027 [5][38]. - Total cash costs and AISC are projected to decrease by 8% by 2027, with improvements expected in the second half of 2026 [6][38]. Growth Pipeline - The Oko West Project is fully funded and on schedule, with total project commitments of approximately $424 million, targeting first gold pour in the second half of 2027 [10][25]. - Gurupi's development roadmap includes a $21 million exploration budget for 2026, aiming for an updated Mineral Resource Estimate and Preliminary Economic Assessment by year-end [10][33]. Exploration Activities - The company executed a significant exploration program in 2025, with total expenditures of $16 million, focusing on both near-mine and regional targets [34][35]. - Notable drilling results included intercepts of 27.0 m at 0.85 g/t Au and 23.0 m at 0.91 g/t Au, indicating potential for resource expansion [35][36]. Environmental, Social & Governance (ESG) Highlights - The company maintained a strong safety record with a Total Recordable Injury Frequency Rate (TRIFR) of 0.23 in 2025, reflecting its commitment to health and safety [42][43]. - Local hiring initiatives were emphasized, with 82.6% of the workforce at Tocantinzinho being from the state of Pará, Brazil [43].

Core Insights - AFL Group achieved record results in fiscal year 2025, doubling its net profit to €10.8 million, reflecting a 100% year-on-year increase [2][6] Financial Performance - Net banking income reached €30.8 million, up 28% year-on-year, while operating expenses increased by 8% to €17.5 million [2][3] - Gross operating income surged by 69% to €13.3 million, and net income before tax rose by 78% to €13.3 million [2][3] - The cost/income ratio improved to 64.4% from 67.8% in the previous year [2] Capital Structure - AFL Group's committed capital increased by 9% to €356 million, supported by four capital increases in 2025 [3] - The Common Equity Tier 1 (CET1) ratio stood at 59.45%, with the Tier 1 ratio at 61.33% [3][4] Liquidity Position - The liquidity reserve as of December 31, 2025, allows AFL to meet its needs for 12 months without market recourse, with a Liquidity Coverage Ratio (LCR) of 485% and a Net Stable Funding Ratio (NSFR) of 157% [5] Credit Activity - Outstanding loans reached €10.7 billion by the end of 2025, driven by competitive credit offers to shareholders [7] - Medium-long-term loan origination totaled €1.832 billion, with short-term credit lines amounting to €635 million [3] Market Position and Ratings - AFL's debt was upgraded to HQLA 1 in 2024, and in 2025, Fitch Ratings revised its long-term rating to A+ with a stable outlook, while S&P Global Ratings also adjusted its rating to A+/A-1 [10][13] - The average cost of funding narrowed significantly to 15.6 basis points above the OAT curve, down from 32.5 basis points in 2024 [8] Sustainable Finance Initiatives - AFL revamped its sustainable bond issuance framework in 2025, raising a cumulative total of €2.25 billion since 2020 through sustainable bonds [22][24] - The 2025 Sustainable Bond Report details the allocation and impact of funds raised, contributing to the United Nations Sustainable Development Goals [24][25]

Core Insights - Unibail-Rodamco-Westfield N.V. has released its 2025 Annual Report, which includes the Management Board Report and audited Financial Statements for the fiscal year ending December 31, 2025 [1]. Group 1: Company Overview - URW NV's portfolio includes assets located in the United States and The Netherlands [2]. - URW NV, along with its consolidated entities and Unibail-Rodamco-Westfield SE, forms the Unibail-Rodamco-Westfield Group [2]. - URW SE consolidates URW NV and its controlled undertakings, providing a comprehensive overview in its 2025 Universal Registration Document [2].

Core Insights - Liberty Gold Corp. reported its financial and operational results for the fiscal year ended December 31, 2025, highlighting advancements in the Black Pine Gold Project and strategic corporate initiatives [1][2]. Recent Project Highlights – Black Pine - The Black Pine Gold Project has seen resource growth, the initiation of a feasibility study, and key federal permitting milestones [2]. - An updated independent Mineral Resource Estimate (MRE) reported an Indicated Resource of 502.7 million tonnes at an average grade of 0.30 g/t Au, totaling 4,882,000 ounces Au, and an Inferred Resource of 157.1 million tonnes at 0.21 g/t Au, totaling 1,050,000 ounces Au [3]. - A high-grade subset of the MRE includes an Indicated Resource of 60.1 million tonnes at 0.99 g/t Au, totaling 1,907,000 ounces Au, and an Inferred Resource of 6.4 million tonnes at 0.74 g/t Au, totaling 152,000 ounces Au [3]. - The project was accepted into the FAST-41 permitting framework, providing a coordinated permitting review and a revised timetable [3]. - A feasibility study commenced with M3 Engineering & Technology Corp. as the lead consultant [3]. - Significant drilling results confirmed the expansion of the Rangefront Zone, with notable intercepts including 0.41 g/t Au over 41.1 m [3]. Recent Corporate Highlights - Liberty Gold received a first staged payment of $2.21 million from the sale of its interest in the TV Tower copper-gold project [6]. - The company appointed Mr. Brad Ralph as Senior Vice President, Corporate Development, and promoted Ms. Susie Bell and Mr. Matthew Zietlow to Vice President roles [6]. - The company entered into a definitive share purchase agreement to sell its subsidiary, Specialty American Metals Inc., for $72.5 million, including cash and shares [6]. - An asset purchase agreement was made with Blue Moon Metals Inc. for the Gage Project, involving common shares and a net smelter return royalty [6]. Selected Financial Data - For the year ended December 31, 2025, the company reported a loss from continuing operations of $23.3 million, compared to $15.9 million in 2024 [9]. - Cash and short-term investments increased to $28.1 million from $7.0 million in 2024 [9]. - Total assets rose to $44.1 million, up from $24.4 million in 2024, while shareholders' equity increased to $37.5 million from $21.2 million [9].

Core Insights - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The company’s lead candidate, ONP-002, is in Phase IIa clinical development for treating concussion and mild traumatic brain injury (mTBI), which affects approximately 69 million people globally each year without any approved pharmacological treatment [3] - The company received an unqualified audit opinion from its independent accounting firm regarding its financial statements, which included a paragraph about its ability to continue as a going concern [1] Financial Information - The audited consolidated financial statements for the fiscal year ended December 31, 2025, were filed on March 16, 2026, with the Securities and Exchange Commission [1][2] - The announcement regarding the audit opinion is made in compliance with NYSE American LLC Company Guide Section 610(b) [1] Company Overview - Oragenics is exploring the expansion of its central nervous system (CNS) pipeline strategy through both internal development and strategic business development [3] - The company’s intranasal delivery platform aims to provide rapid, non-invasive delivery of therapeutics directly to the brain, bypassing the blood-brain barrier [3]